Work

Intravenous IRON therapy outcomes according to iron deficiency type in HEART failure (IRON-HEART)

Year: 2026
Type: article
Abstract: Objective Intravenous iron is recommended for heart failure (HF) with iron deficiency. A recent framework describes three mechanistic iron-deficiency phenotypes, but their clinical relevance and the prognostic value of the change in transferrin saturation (ΔTSAT) after intravenous iron are unknown. We examined both in patients treated with ferric carboxymaltose (FCM). Methods In this retrospective single-center cohort, 146 patients with chronic HF received a single 1,000 mg dose of FCM and were classified into non-mutually exclusive, study-defined Type 1–3 phenotypes. The primary outcome was a composite of all-cause death, HF hospitalization, or emergency department visit for worsening HF within 1 year. Associations were estimated with logistic regression adjusted for age, sex, left ventricular ejection fraction, NYHA class, and anemia, with sensitivity analyses including Cox regression over the protocol-defined follow-up (to 1 year after the post-treatment TSAT measurement). ΔTSAT analyses were exploratory. Results The composite outcome occurred in 32 patients (21.9%). No phenotype was significantly associated with the outcome: Type 1 (adjusted odds ratio [OR] 2.60, 95% confidence interval [CI] 0.84–8.01), Type 2 (OR 0.40, 95% CI 0.11–1.42), and Type 3 (OR 0.66, 95% CI 0.21–2.11); NYHA class III–IV showed a borderline association (OR 3.41, 95% CI 0.95–12.18). Over the longer protocol-defined follow-up (40 events), the hazard ratio for Type 1 was 2.99 (95% CI 1.19–7.51). Among 139 patients with post-treatment TSAT, ΔTSAT was not associated with the outcome (adjusted OR per 10-point increase 1.00, 95% CI 0.80–1.24), with no effect modification by phenotype (global p = 0.37); however, in 22 of 27 patients with an event, the event preceded the post-treatment measurement. Discrimination (area under the receiver operating characteristic curve) was poor for baseline TSAT (0.57), ΔTSAT (0.50), and ferritin (0.44). Conclusion Operationally defined phenotypes were not significantly associated with the 1-year composite outcome; marked hypoferremia (Type 1) demonstrated a consistent directional signal across analyses, although estimates were imprecise and require prospective validation. Because most events preceded the post-treatment TSAT measurement, the prognostic value of the TSAT response could not be assessed. The present results should be considered exploratory owing to limited sample size and event rates.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236802265
FWCI:
Cites: 34
Cited by:
Related to: 10
Parts: 2